Laprade N, Soghomonian J J
Département d'anatomie, Université Laval, Québec, Canada.
Brain Res Mol Brain Res. 1995 Dec 1;34(1):65-74. doi: 10.1016/0169-328x(95)00139-j.
The effects of in vivo administration of dopamine receptor agonists or antagonists on the mRNA levels encoding for the two isoforms of glutamate decarboxylase, GAD65 and GAD67, and for preproenkephalin were studied in regions of the rat dorsal striatum by radioactive in situ hybridization histochemistry. Changes in striatal mRNA levels after drug treatment were quantified by computerized densitometry on X-ray films. Chronic administration of the dopamine receptor agonist apomorphine or the D1 dopamine receptor agonist SKF-38393 resulted in increased GAD65 mRNA levels in the dorsomedial, ventromedial, dorsolateral and ventrolateral sectors of the striatum. Apomorphine or SKF-38393 treatment did not induce significant effects on GAD67 and preproenkephalin mRNA levels in striatum. On the other hand, chronic administration of the D2 dopamine receptor agonist quinpirole significantly decreased GAD67 in the dorsolateral and ventrolateral and preproenkephalin in the ventrolateral sectors of the striatum. Quinpirole treatment did not induce significant changes in GAD65 mRNA levels. Chronic administration of the dopamine receptor antagonist haloperidol resulted in a significant increase in GAD67 and preproenkephalin mRNA levels in the dorsomedial, dorsolateral and ventrolateral striatal sectors. Chronic treatment with the D2/D3 dopamine receptor antagonist sulpiride resulted in a significant increase in GAD67 in the ventromedial and ventrolateral and PPE in the dorsomedial and ventrolateral striatal sectors. Haloperidol or sulpiride did not induce significant changes in striatal GAD65 mRNA levels. Chronic administration of the D1 dopamine receptor antagonist SCH-23390 had no significant effect on GAD67, GAD65 or preproenkephalin mRNA levels. In the present experimental conditions, stimulation of dopamine receptors with apomorphine or SKF-38393 resulted in increased GAD65 mRNA levels whereas blockade of dopamine receptors with haloperidol or sulpiride resulted in increased GAD67 mRNA levels. These results indicate that striatal GAD65 and GAD67 mRNA levels are differentially regulated by dopamine receptor subtypes.
通过放射性原位杂交组织化学方法,研究了在大鼠背侧纹状体区域体内给予多巴胺受体激动剂或拮抗剂对编码谷氨酸脱羧酶两种同工型(GAD65和GAD67)以及前脑啡肽原的mRNA水平的影响。药物治疗后纹状体mRNA水平的变化通过X射线胶片上的计算机密度测定法进行定量。长期给予多巴胺受体激动剂阿扑吗啡或D1多巴胺受体激动剂SKF - 38393导致纹状体背内侧、腹内侧、背外侧和腹外侧区域的GAD65 mRNA水平升高。阿扑吗啡或SKF - 38393治疗对纹状体中的GAD67和前脑啡肽原mRNA水平未产生显著影响。另一方面,长期给予D2多巴胺受体激动剂喹吡罗可显著降低纹状体背外侧和腹外侧区域的GAD67以及腹外侧区域的前脑啡肽原。喹吡罗治疗未引起GAD65 mRNA水平的显著变化。长期给予多巴胺受体拮抗剂氟哌啶醇导致纹状体背内侧、背外侧和腹外侧区域的GAD67和前脑啡肽原mRNA水平显著升高。长期用D2/D3多巴胺受体拮抗剂舒必利治疗导致纹状体腹内侧和腹外侧区域的GAD67以及背内侧和腹外侧区域的前脑啡肽原显著升高。氟哌啶醇或舒必利未引起纹状体GAD65 mRNA水平的显著变化。长期给予D1多巴胺受体拮抗剂SCH - 23390对GAD67、GAD65或前脑啡肽原mRNA水平无显著影响。在本实验条件下,用阿扑吗啡或SKF - 38393刺激多巴胺受体会导致GAD65 mRNA水平升高,而用氟哌啶醇或舒必利阻断多巴胺受体会导致GAD67 mRNA水平升高。这些结果表明,纹状体GAD65和GAD67 mRNA水平受多巴胺受体亚型的不同调节。